Jonathan Newman

Dr. Jonathan Newman

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
DMDavid J. Maron
David J. Maron
JHJudith S. Hochman
Judith S. Hochman
HRHarmony R. Reynolds
Harmony R. Reynolds
SBSripal Bangalore
Sripal Bangalore
SOSean M. O’brien
Sean M. O’brien
YRYves Rosenberg
Yves Rosenberg
Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain.

18 June 2020 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
HRHarmony R. Reynolds
Harmony R. Reynolds
SASamrachana Adhikari
Samrachana Adhikari
CPClaudia Pulgarin
Claudia Pulgarin
ATAndrea B. Troxel
Andrea B. Troxel
EIEduardo Iturrate
Eduardo Iturrate
JHJudith S. Hochman
Judith S. Hochman
There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2). We assessed the relation between previous treatment with ACE inhibitors, angiotensin-receptor blockers, beta-blockers, calcium-channel blockers, or thiazide diuretics and the likelihood of a positive or negative result on Covid-19 testing as well as the likelihood of severe illness (defined as intensive care, mechanical ventilation, or death) among patients who tested positive. Using Bayesian methods, we compared outcomes in patients who had been treated with these medications and in untreated patients, overall and in those with hypertension, after propensity-score matching for receipt of each medication class. A difference of at least 10 percentage points was prespecified as a substantial difference. Among 12,594 patients who were tested for Covid-19, a total of 5894 (46.8%) were positive; 1002 of these patients (17.0%) had severe illness. A history of hypertension was present in 4357 patients (34.6%), among whom 2573 (59.1%) had a positive test; 634 of these patients (24.6%) had severe illness. There was no association between any single medication class and an increased likelihood of a positive test. None of the medications examined was associated with a substantial increase in the risk of severe illness among patients who tested positive. We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications.

30 March 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
SBSripal Bangalore
Sripal Bangalore
DMDavid J. Maron
David J. Maron
SOSean M. O’bRien
Sean M. O’bRien
JFJerome L. Fleg
Jerome L. Fleg
EKEvgeny I. Kretov
Evgeny I. Kretov
JHJudith S. Hochman
Judith S. Hochman
Clinical trials that have assessed the effect of revascularization in patients with stable coronary disease have routinely excluded those with advanced chronic kidney disease.

30 March 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
JSJohn A. Spertus
John A. Spertus
PJPhilip G. Jones
Philip G. Jones
DMDavid J. Maron
David J. Maron
SOSean M. O’bRien
Sean M. O’bRien
HRHarmony R. Reynolds
Harmony R. Reynolds
DMDaniel B. Mark
Daniel B. Mark
In the ISCHEMIA trial, an invasive strategy with angiographic assessment and revascularization did not reduce clinical events among patients with stable ischemic heart disease and moderate or severe ischemia. A secondary objective of the trial was to assess angina-related health status among these patients.

12 May 2020 in Circulation
Verified
Journal Article
Open access
PDF file
SASuzanne V. Arnold
Suzanne V. Arnold
DBDeepak L. Bhatt
Deepak L. Bhatt
GBGregory W. Barsness
Gregory W. Barsness
ABAlexis L. Beatty
Alexis L. Beatty
PDPrakash C. Deedwania
Prakash C. Deedwania
CCCouncil On Clinical Cardiology
Council On Clinical Cardiology
Although cardiologists have long treated patients with coronary artery disease (CAD) and concomitant type 2 diabetes mellitus (T2DM), T2DM has traditionally been considered just a comorbidity that affected the development and progression of the disease. Over the past decade, a number of factors have shifted that have forced the cardiology community to reconsider the role of T2DM in CAD. First, in addition to being associated with increased cardiovascular risk, T2DM has the potential to affect a number of treatment choices for CAD. In this document, we discuss the role that T2DM has in the selection of testing for CAD, in medical management (both secondary prevention strategies and treatment of stable angina), and in the selection of revascularization strategy. Second, although glycemic control has been recommended as a part of comprehensive risk factor management in patients with CAD, there is mounting evidence that the mechanism by which glucose is managed can have a substantial impact on cardiovascular outcomes. In this document, we discuss the role of glycemic management (both in intensity of control and choice of medications) in cardiovascular outcomes. It is becoming clear that the cardiologist needs both to consider T2DM in cardiovascular treatment decisions and potentially to help guide the selection of glucose-lowering medications. Our statement provides a comprehensive summary of effective, patient-centered management of CAD in patients with T2DM, with emphasis on the emerging evidence. Given the increasing prevalence of T2DM and the accumulating evidence of the need to consider T2DM in treatment decisions, this knowledge will become ever more important to optimize our patients’ cardiovascular outcomes.

1 December 2014 in American Heart Journal
Verified
Journal Article
Open access
NSNatalia V. Solenkova
Natalia V. Solenkova
JNJonathan Newman
Jonathan Newman
JBJeffrey S. Berger
Jeffrey S. Berger
GTGeorge Thurston
George Thurston
JHJudith S. Hochman
Judith S. Hochman
GLGervasio A. Lamas
Gervasio A. Lamas
There is epidemiological evidence that metal contaminants may play a role in the development of atherosclerosis and its complications. Moreover, a recent clinical trial of a metal chelator had a surprisingly positive result in reducing cardiovascular events in a secondary prevention population, strengthening the link between metal exposure and cardiovascular disease (CVD). This is, therefore, an opportune moment to review evidence that exposure to metal pollutants, such as arsenic, lead, cadmium, and mercury, is a significant risk factor for CVD. We reviewed the English-speaking medical literature to assess and present the epidemiological evidence that 4 metals having no role in the human body (xenobiotic), mercury, lead, cadmium, and arsenic, have epidemiologic and mechanistic links to atherosclerosis and CVD. Moreover, we briefly review how the results of the Trial to Assess Chelation Therapy (TACT) strengthen the link between atherosclerosis and xenobiotic metal contamination in humans. There is strong evidence that xenobiotic metal contamination is linked to atherosclerotic disease and is a modifiable risk factor.